ArticleStructure (London, England : 1993)2010
Developing three-dimensional models of putative-folding intermediates of the HDV ribozyme.
Article in Structure (London, England : 1993), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Determining RNA three-dimensional structures using low-resolution data.Journal of structural biology · 2012Article
- The mechanisms of RNA SHAPE chemistry.Journal of the American Chemical Society · 2012Article
- Dynamic energy landscapes of riboswitches help interpret conformational rearrangements and function.PLoS computational biology · 2012Article
- Characterization of the trans Watson-Crick GU base pair located in the catalytic core of the antigenomic HDV ribozyme.PloS one · 2012Article
- Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.Nucleic acid therapeutics · 2011Article
- Topological constraints: using RNA secondary structure to model 3D conformation, folding pathways, and dynamic adaptation.Current opinion in structural biology · 2011Review
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Both the role and the interacting partners of an RNA molecule can change depending on its tertiary structure. Consequently, it is important to be able to accurately predict the complete folding pathway of an RNA molecule. The hepatitis delta virus (HDV) ribozyme is a small catalytic RNA with the greatest number of folding intermediates making it the model of choice with which to address this problem. The tertiary structures of the known putative intermediates along the folding pathway of the HDV ribozyme were predicted using the Macromolecular Conformations Symbolic programming (MC-Sym) software. The structures obtained by this method received physical support from Selective 2'-Hydroxyl Acylation analyzed by Primer Extension (SHAPE). The analysis of these structures elucidated several features of the HDV ribozyme. In addition, this report represents an application for MC-Sym that permits progression one step further toward the computer prediction of an RNA molecule-folding pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.